\-\ Texto\\:\\ \ \(0\)\
\-\ abd\\:\\ midepigastric\\ tenderness\\.\ \(0\)\
\-\ labs\\:\\ hyperbilirubinemia\\.\\ mildly\\ elevated\\ lfts\\.\\ elevated\\ amylase\\ and\\ lipase\\.\ \(0\)\
\-\ therapy\\ for\\ underlying\\ metastatic\\ pancreatic\\ carcinoma\\.\ \(0\)\
\-\ ct\\:\\ cavernous\\ transformation\\ of\\ the\\ thrombosed\\ portal\\ vein\\ occurs\\ when\\ small\\ collateral\\ veins\\ adjacent\\ to\\ the\\ portal\\ vein\\ expand\\ and\\ replace\\ the\\ obliterated\\ portal\\ vein\\.\\ in\\ this\\ case\\,\\ pv\\ thrombosis\\ is\\ secondary\\ to\\ a\\ pancreatic\\ primary\\ neoplasm\\ with\\ evidence\\ of\\ metastatic\\ spread\\.\\ the\\ pv\\ thrombus\\ may\\ be\\ secondary\\ to\\ direct\\ tumor\\ extension\\ or\\ may\\ be\\ the\\ sequelae\\ of\\ a\\ paraneoplastic\\ syndrome\\ \\(hypercoagulable\\ state\\)\\.\\ peripheral\\ hypodense\\ liver\\ lesions\\ are\\ likely\\ metastases\\.\ \(0\)\
\-\ portal\\ vein\\ thrombosis\\ with\\ cavernous\\ transformation\\ in\\ metastatic\\ pancreatic\\ cancer\ \(0\)\
\-\ 1\\.\\ \\ tumor\\:\\ direct\\ invasion\\ of\\ the\\ pv\\,\\ pv\\ compression\\ or\\ paraneoplastic\\ hypercoagulability\\ \ \(0\)\
\-\ 2\\.\\ \\ cirrhosis\ \(0\)\
\-\ 3\\.\\ \\ infection\\ \\(esp\\.\\ in\\ children\\)\ \(0\)\
\-\ 4\\.\\ \\ inflammation\\ \\(pancreatitis\\)\ \(0\)\
\-\ 5\\.\\ \\ inherited\\ coagulation\\ disorders\ \(0\)\
\-\ 6\\.\\ \\ idiopathic\ \(0\)\
\-\ 51\\ year\\ old\\ asian\\ woman\\ with\\ right\\ upper\\ quadrant\\ abdominal\\ pain\\,\\ nausea\\.\\ 20\\ lb\\ weightloss\\.\ \(0\)\
\-\ portal\\ vein\\ obstruction\\ does\\ not\\ affect\\ liver\\ function\\ unless\\ the\\ patient\\ has\\ an\\ underlying\\ liver\\ disease\\ such\\ as\\ cirrhosis\\.\\ this\\ is\\ partially\\ due\\ to\\ a\\ rapid\\ arterial\\ buffer\\ response\\,\\ with\\ compensatory\\ increased\\ flow\\ of\\ the\\ hepatic\\ artery\\ maintaining\\ the\\ total\\ hepatic\\ blood\\ flow\\.\\ formation\\ of\\ collaterals\\ occurs\\ rather\\ rapidly\\ as\\ well\\,\\ and\\ they\\ have\\ been\\ described\\ as\\ early\\ as\\ 12\\ days\\ after\\ acute\\ thrombosis\\,\\ though\\ the\\ average\\ time\\ to\\ formation\\ is\\ approximately\\ 5\\ weeks\\.\\ \ \(0\)\
\-\ the\\ development\\ of\\ a\\ collateral\\ circulation\\,\\ with\\ its\\ attendant\\ risk\\ of\\ variceal\\ hemorrhage\\,\\ is\\ responsible\\ for\\ most\\ of\\ the\\ complications\\ and\\ is\\ the\\ most\\ common\\ manifestation\\ of\\ portal\\ vein\\ obstruction\\.\\ other\\ sequelae\\ of\\ the\\ subsequent\\ portal\\ hypertension\\,\\ such\\ as\\ ascites\\,\\ are\\ less\\ frequent\\.\\ rarely\\,\\ the\\ thrombosis\\ extends\\ from\\ the\\ portal\\ vein\\ to\\ the\\ mesenteric\\ arcades\\,\\ leading\\ to\\ bowel\\ ischemia\\ and\\ infarction\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ portal\\:\\ 0\\.11387418507418198\ \(0\)\
\-\ pv\\:\\ 0\\.10281482586590573\ \(0\)\
\-\ vein\\:\\ 0\\.06849219384208488\ \(0\)\
\-\ thrombosis\\:\\ 0\\.046430682875355\ \(0\)\
\-\ pancreatic\\:\\ 0\\.03969103894686895\ \(0\)\
\-\ paraneoplastic\\:\\ 0\\.03909152591361544\ \(0\)\
\-\ sequelae\\:\\ 0\\.03213828358027297\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.03184385310157112\ \(0\)\
\-\ transformation\\:\\ 0\\.03066599057224289\ \(0\)\
\-\ collateral\\:\\ 0\\.02830198102603047\ \(0\)\
\-\ liver\\:\\ 0\\.027970457381323328\ \(0\)\
\-\ buffer\\:\\ 0\\.027897210202425627\ \(0\)\
\-\ attendant\\:\\ 0\\.027897210202425627\ \(0\)\
\-\ variceal\\:\\ 0\\.027897210202425627\ \(0\)\
\-\ arcades\\:\\ 0\\.027897210202425627\ \(0\)\
\-\ weightloss\\:\\ 0\\.025703706466476434\ \(0\)\
\-\ direct\\:\\ 0\\.025546803359841573\ \(0\)\
\-\ cavernous\\:\\ 0\\.025085368101562536\ \(0\)\
\-\ midepigastric\\:\\ 0\\.024420589035754392\ \(0\)\
\-\ underlying\\:\\ 0\\.02317865081942227\ \(0\)\
\-\ hyperbilirubinemia\\:\\ 0\\.022804052251684803\ \(0\)\
\-\ hepatic\\:\\ 0\\.022585407289911468\ \(0\)\
\-\ formation\\:\\ 0\\.022324375906784575\ \(0\)\
\-\ occurs\\:\\ 0\\.022197789408641096\ \(0\)\
\-\ replace\\:\\ 0\\.021739266692756914\ \(0\)\
\-\ esp\\:\\ 0\\.021739266692756914\ \(0\)\
\-\ expand\\:\\ 0\\.02094396786908316\ \(0\)\
\-\ hypercoagulability\\:\\ 0\\.02094396786908316\ \(0\)\
\-\ maintaining\\:\\ 0\\.02061054851573561\ \(0\)\
\-\ as\\:\\ 0\\.02045217572617291\ \(0\)\
\-\ metastatic\\:\\ 0\\.020421924717874275\ \(0\)\
\-\ obliterated\\:\\ 0\\.02030893402268395\ \(0\)\
\-\ hypercoagulable\\:\\ 0\\.02030893402268395\ \(0\)\
\-\ inherited\\:\\ 0\\.019780281856028356\ \(0\)\
\-\ compensatory\\:\\ 0\\.019327431085013568\ \(0\)\
\-\ coagulation\\:\\ 0\\.01912319525862885\ \(0\)\
\-\ obstruction\\:\\ 0\\.01907215220626225\ \(0\)\
\-\ lb\\:\\ 0\\.0189313451895895\ \(0\)\
\-\ collaterals\\:\\ 0\\.0189313451895895\ \(0\)\
\-\ thrombosed\\:\\ 0\\.018417044779786413\ \(0\)\
\-\ elevated\\:\\ 0\\.01835010355290546\ \(0\)\
\-\ flow\\:\\ 0\\.017873758714294405\ \(0\)\
\-\ lfts\\:\\ 0\\.017840077827906812\ \(0\)\
\-\ asian\\:\\ 0\\.017586778120079163\ \(0\)\
\-\ responsible\\:\\ 0\\.017586778120079163\ \(0\)\
\-\ manifestation\\:\\ 0\\.01746734670241193\ \(0\)\
\-\ such\\:\\ 0\\.01690716955595476\ \(0\)\
\-\ amylase\\:\\ 0\\.01664610874201609\ \(0\)\
\-\ lipase\\:\\ 0\\.016556960397184774\ \(0\)\
\-\ circulation\\:\\ 0\\.016470254782665422\ \(0\)\
\-\ average\\:\\ 0\\.015781256416067733\ \(0\)\
\-\ affect\\:\\ 0\\.0155813231830882\ \(0\)\
\-\ ascites\\:\\ 0\\.015517390564994784\ \(0\)\
\-\ state\\:\\ 0\\.015273842966462734\ \(0\)\
\-\ secondary\\:\\ 0\\.015120442826005111\ \(0\)\
\-\ rapidly\\:\\ 0\\.014993610696394868\ \(0\)\
\-\ pancreatitis\\:\\ 0\\.014836658351017109\ \(0\)\
\-\ 51\\:\\ 0\\.014687123905287534\ \(0\)\
\-\ unless\\:\\ 0\\.014638809120063519\ \(0\)\
\-\ hypodense\\:\\ 0\\.014407716920649313\ \(0\)\
\-\ abd\\:\\ 0\\.014319806907652239\ \(0\)\
\-\ \\:\\:\\ 0\\.01430727615178057\ \(0\)\
\-\ thrombus\\:\\ 0\\.013657306182393143\ \(0\)\
\-\ rapid\\:\\ 0\\.013657306182393143\ \(0\)\
\-\ response\\:\\ 0\\.01355354092029507\ \(0\)\
\-\ frequent\\:\\ 0\\.013519695068659793\ \(0\)\
\-\ 6\\.\\:\\ 0\\.013139491550172251\ \(0\)\
\-\ spread\\:\\ 0\\.013080339230513539\ \(0\)\
\-\ invasion\\:\\ 0\\.013022272335993929\ \(0\)\
\-\ rarely\\:\\ 0\\.012965251748960138\ \(0\)\
\-\ veins\\:\\ 0\\.012937122168525815\ \(0\)\
\-\ disorders\\:\\ 0\\.012937122168525815\ \(0\)\
\-\ leading\\:\\ 0\\.012937122168525815\ \(0\)\
\-\ rather\\:\\ 0\\.012854203268544728\ \(0\)\
\-\ tumor\\:\\ 0\\.012609065200068425\ \(0\)\
\-\ ischemia\\:\\ 0\\.012567504232619958\ \(0\)\
\-\ though\\:\\ 0\\.012542684050781268\ \(0\)\
\-\ most\\:\\ 0\\.01248629836536757\ \(0\)\
\-\ mesenteric\\:\\ 0\\.012469370572042237\ \(0\)\
\-\ partially\\:\\ 0\\.012374188751671103\ \(0\)\
\-\ idiopathic\\:\\ 0\\.012327650310564472\ \(0\)\
\-\ may\\:\\ 0\\.011862837777836227\ \(0\)\
\-\ arterial\\:\\ 0\\.011836533571938833\ \(0\)\
\-\ development\\:\\ 0\\.011777747541644734\ \(0\)\
\-\ extends\\:\\ 0\\.011720033656993529\ \(0\)\
\-\ children\\:\\ 0\\.011682134318238098\ \(0\)\
\-\ 5\\.\\:\\ 0\\.01166335350963109\ \(0\)\
\-\ total\\:\\ 0\\.011644683502899482\ \(0\)\
\-\ metastases\\:\\ 0\\.011552950791275267\ \(0\)\
\-\ mildly\\:\\ 0\\.011516989529723637\ \(0\)\
\-\ described\\:\\ 0\\.011516989529723637\ \(0\)\
\-\ inflammation\\:\\ 0\\.011499160992640547\ \(0\)\
\-\ function\\:\\ 0\\.011463802446443948\ \(0\)\
\-\ 12\\:\\ 0\\.011067716551019879\ \(0\)\
\-\ infarction\\:\\ 0\\.011052241914012943\ \(0\)\
\-\ nausea\\:\\ 0\\.010886835494564345\ \(0\)\
\-\ complications\\:\\ 0\\.010715736693076131\ \(0\)\
\-\ hypertension\\:\\ 0\\.010660699532595531\ \(0\)\
\-\ 4\\.\\:\\ 0\\.010647088513926576\ \(0\)\
\-\ subsequent\\:\\ 0\\.010527154106993074\ \(0\)\
\-\ \\,\\:\\ 0\\.010280129070276737\ \(0\)\
\-\ its\\:\\ 0\\.010204213428657093\ \(0\)\
\-\ compression\\:\\ 0\\.0101226181212023\ \(0\)\
\-\ early\\:\\ 0\\.00988974357481784\ \(0\)\
\-\ risk\\:\\ 0\\.009794957744807235\ \(0\)\
\-\ peripheral\\:\\ 0\\.009784599120297839\ \(0\)\
\-\ they\\:\\ 0\\.009743500400276285\ \(0\)\
\-\ 20\\:\\ 0\\.009723149481509544\ \(0\)\
\-\ extension\\:\\ 0\\.009652934560701435\ \(0\)\
\-\ quadrant\\:\\ 0\\.009517012449322957\ \(0\)\
\-\ to\\:\\ 0\\.009460369490825645\ \(0\)\
\-\ labs\\:\\ 0\\.009404981034604867\ \(0\)\
\-\ 3\\.\\:\\ 0\\.009252766494116226\ \(0\)\
\-\ does\\:\\ 0\\.009226648956911412\ \(0\)\
\-\ neoplasm\\:\\ 0\\.009209356252885848\ \(0\)\
\-\ less\\:\\ 0\\.009158037988362918\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.009000811975240618\ \(0\)\
\-\ is\\:\\ 0\\.00889700598710009\ \(0\)\
\-\ cancer\\:\\ 0\\.008889763494825207\ \(0\)\
\-\ 2\\.\\:\\ 0\\.008599506777848919\ \(0\)\
\-\ adjacent\\:\\ 0\\.008550114696627427\ \(0\)\
\-\ bowel\\:\\ 0\\.008480865610394808\ \(0\)\
\-\ 1\\.\\:\\ 0\\.008446801159169622\ \(0\)\
\-\ approximately\\:\\ 0\\.008366512109353111\ \(0\)\
\-\ be\\:\\ 0\\.0083402324262274\ \(0\)\
\-\ days\\:\\ 0\\.008288209798012586\ \(0\)\
\-\ tenderness\\:\\ 0\\.00822440608506846\ \(0\)\
\-\ artery\\:\\ 0\\.008052310101608224\ \(0\)\
\-\ primary\\:\\ 0\\.0080107096927079\ \(0\)\
\-\ 5\\:\\ 0\\.007911900071025834\ \(0\)\
\-\ infection\\:\\ 0\\.007860811943268377\ \(0\)\
\-\ when\\:\\ 0\\.007744719106379765\ \(0\)\
\-\ syndrome\\:\\ 0\\.007733881571945068\ \(0\)\
\-\ weeks\\:\\ 0\\.007674929610446672\ \(0\)\
\-\ carcinoma\\:\\ 0\\.007664328069670464\ \(0\)\
\-\ time\\:\\ 0\\.0076379785672130145\ \(0\)\
\-\ likely\\:\\ 0\\.007627499892201444\ \(0\)\
\-\ the\\:\\ 0\\.007437461518865945\ \(0\)\
\-\ blood\\:\\ 0\\.007381047697814239\ \(0\)\
\-\ are\\:\\ 0\\.007372619446389885\ \(0\)\
\-\ been\\:\\ 0\\.007356945852734149\ \(0\)\
\-\ lesions\\:\\ 0\\.007239115526404898\ \(0\)\
\-\ therapy\\:\\ 0\\.007229875937470294\ \(0\)\
\-\ due\\:\\ 0\\.007216066939724176\ \(0\)\
\-\ evidence\\:\\ 0\\.007090008175211639\ \(0\)\
\-\ common\\:\\ 0\\.0070767949745455605\ \(0\)\
\-\ \\(\\:\\ 0\\.0068578644896569035\ \(0\)\
\-\ \\)\\:\\ 0\\.00677409201373391\ \(0\)\
\-\ abdominal\\:\\ 0\\.006759238095323149\ \(0\)\
\-\ acute\\:\\ 0\\.006676833319957263\ \(0\)\
\-\ increased\\:\\ 0\\.006615458170252075\ \(0\)\
\-\ upper\\:\\ 0\\.0065255712195212605\ \(0\)\
\-\ or\\:\\ 0\\.006338751575719667\ \(0\)\
\-\ woman\\:\\ 0\\.006246528314838311\ \(0\)\
\-\ other\\:\\ 0\\.006233033381969774\ \(0\)\
\-\ small\\:\\ 0\\.006229668621459236\ \(0\)\
\-\ well\\:\\ 0\\.006117344787875478\ \(0\)\
\-\ this\\:\\ 0\\.006083146919709703\ \(0\)\
\-\ case\\:\\ 0\\.005916153268567312\ \(0\)\
\-\ have\\:\\ 0\\.005855816703686999\ \(0\)\
\-\ after\\:\\ 0\\.0055949405145860834\ \(0\)\
\-\ has\\:\\ 0\\.005078164463589487\ \(0\)\
\-\ a\\:\\ 0\\.005020250655931662\ \(0\)\
\-\ for\\:\\ 0\\.004614608535713387\ \(0\)\
\-\ disease\\:\\ 0\\.004420055510176279\ \(0\)\
\-\ of\\:\\ 0\\.004055512053094534\ \(0\)\
\-\ from\\:\\ 0\\.004007707953019659\ \(0\)\
\-\ in\\:\\ 0\\.004000606615255585\ \(0\)\
\-\ not\\:\\ 0\\.003907654024499795\ \(0\)\
\-\ ct\\:\\ 0\\.003782606498076085\ \(0\)\
\-\ an\\:\\ 0\\.0037394457730529425\ \(0\)\
\-\ pain\\:\\ 0\\.003302557492185869\ \(0\)\
\-\ year\\:\\ 0\\.003025649586306692\ \(0\)\
\-\ right\\:\\ 0\\.002853264902248154\ \(0\)\
\-\ and\\:\\ 0\\.0028482437615857353\ \(0\)\
\-\ old\\:\\ 0\\.002768780369817261\ \(0\)\
\-\ patient\\:\\ 0\\.0027107339585961646\ \(0\)\
\-\ \\.\\:\\ 0\\.0020221254738994714\ \(0\)\
\-\ with\\:\\ 0\\.0018513319001564833\ \(0\)\
